Michele C. Livesey,
MBA
Finance Committee Member
Drug Development Strategy and Execution Consultant
Livesey Consulting
Ms. Livesey brings to DIA more than two decades of drug development experience through managing and leading strategy and drug development projects for Genentech, Inc., Barrier Therapeutics, Roche, and Afferent Pharmaceuticals. She has worked on monoclonal antibodies and small molecules in all stages of drug development through commercialization, including collaborations with international partners; her therapeutic experience includes oncology, dermatology, cardiovascular, virology, immunology, and pain. Ms. Livesey is Founder and President of Livesey Consulting, which is focused on helping companies reach important drug development milestones and build and execute strategies. She previously served as Vice President of Development Operations for Afferent Pharmaceuticals, where she was responsible for the staffing and oversight of non-clinical (toxicology, and drug metabolism and pharmacokinetics), chemistry, manufacturing and controls, regulatory, quality assurance, project management, and general business operations.
Ms. Livesey has served DIA for more than a decade as an Annual Meeting speaker, session chair, and track chair, and has also provided leadership to the DIA Project Management Community. Ms. Livesey earned her Masters of Business Administration with honors from Golden Gate University with an emphasis in Marketing and Operations and Supply Chain Management.
Our Leadership
-
PharmD •Chair DIA
Senior Advisor R&D
Bayer AG -
MBA •Immediate Past Chair DIA
President and Chief Executive Officer
Cancer Genetics, Inc. (CGI) -
RPh •Chair-Elect DIA
Head, Product Development Medical Affairs Customer Strategy
F. Hoffmann-La Roche Ltd. -
CPA, CGMA •Secretary/Treasurer DIA
Chief Financial Officer
Katabat -
MS • Global Chief Executive
DIA
-
MD, PhD, DSc •Director DIA
Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety
Eli Lilly and Company, Ltd. -
MPharm •Director DIA
Executive Director, Global Regulatory Policy
Merck Sharp & Dohme (Europe) Inc. -
MD •Director DIA
Chief Scientific Officer
Syneos Health -
CPA •Director DIA
Partner, Life Science Industry Practice Group, RSM US -
MD •Director DIA
Chief Medical Officer
Flagship Pioneering -
PhD •Director DIA
Senior Vice President
QIAGEN -
MD, PhD •Director DIA
Vice President and Senior Managing Director, Development & Medical Affairs, GlaxoSmithKline Japan -
PhD •Director DIA
Chairman and Chief Executive Officer
dMed Company Limited -
PharmD •Director DIA
President, R&D Design and Delivery Innovation, IQVIA
-
PharmD • Chair, Executive Committee
-
CPA • Member, Executive Committee -
MBA • Member, Executive Committee -
RPh • Member, Executive Committee -
MS • Member, Executive Committee
-
CPA • Chair, Audit Committee -
MD, PhD, DSc • Member, Audit Committee -
MPharm • Member, Audit Committee -
PharmD • Member, Audit Committee -
PharmD • Member, Audit Committee
-
PhD • Chair, Council of Regulators
Leadership Committee
Japan Pharmaceuticals and Medical Devices Agency Liaison to the DIA Board -
PhD • Council of Regulators
Leadership Committee
European Medicines Agency Liaison to the DIA Board -
MD • Council of Regulators
Leadership Committee
US Food and Drug Administration Liaison to the DIA Board -
PhD • Council of Regulators
Swissmedic Liaison to the DIA Board
-
MS • Global Chief Executive -
MS, CPA • Chief Financial Officer -
-
DIA EMEA -
PhD • Senior Vice President & Managing Director
DIA South Korea and ASEAN -
PhD • Senior Vice President & Managing Director
DIA Americas -
PhD • Senior Vice President & Managing Director
DIA Japan -
RPh, MBA • Senior Vice President & Managing Director
DIA Greater China